Neoadjuvant therapy alters the biliary microbiome in PDAC

被引：1
|
作者：
Jain, Tejeshwar [1 ]
Dudeja, Vikas [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA
来源：
AMERICAN JOURNAL OF SURGERY | 2021年 / 222卷 / 01期
关键词：
D O I：
10.1016/j.amjsurg.2020.12.050
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
    Shahda, Safi
    Perkins, Susan
    Cramer, Harvey M.
    House, Michael Garrett
    Nakeeb, Attila
    Zyromski, Nicholas J.
    Ceppa, Eugene P.
    Sehdev, Amikar
    Akisik, Fatih
    Lin, Jingmei
    Schmidt, Christian
    Ellsworth, Susannah G.
    O'Neil, Nina
    Link, Kristen
    O'Neil, Bert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer
    Thalji, Sam Z.
    Fernando, Deemantha
    Dua, Kulwinder S.
    Madhavan, Srivats
    Chisholm, Phillip
    Smith, Zachary L.
    Aldakkak, Mohammed
    Christians, Kathleen K.
    Clarke, Callisia N.
    George, Ben
    Kamgar, Mandana
    Erickson, Beth A.
    Hall, William A.
    Evans, Douglas B.
    Tsai, Susan
    ANNALS OF SURGERY, 2023, 278 (06) : E1224 - E1231
  • [23] The Microbiome in PDAC-Vantage Point for Future Therapies?
    Pfisterer, Nina
    Lingens, Catharina
    Heuer, Cathleen
    Dang, Linh
    Neesse, Albrecht
    Ammer-Herrmenau, Christoph
    CANCERS, 2022, 14 (23)
  • [24] PDAC: Detecting altered Microbiome Profiles in Duodenal Fluids
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (04): : 549 - +
  • [25] Neoadjuvant Treatments Increase Risk of Postoperative Thrombosis in PDAC
    Mattila, N.
    Lassila, R.
    Mustonen, H.
    Haglund, C.
    Seppanen, H.
    PANCREAS, 2018, 47 (10) : 1409 - 1409
  • [26] Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer
    Kataoka, Kunio
    Ohno, Eizaburo
    Ishikawa, Takuya
    Yamao, Kentaro
    Mizutani, Yasuyuki
    Iida, Tadashi
    Takami, Hideki
    Maeda, Osamu
    Yamaguchi, Junpei
    Yokoyama, Yukihiro
    Ebata, Tomoki
    Kodera, Yasuhiro
    Kawashima, Hiroki
    CLINICAL ENDOSCOPY, 2024, 57 (01) : 112 - 121
  • [27] Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head
    Kirkpatrick, Stacey
    Gillies, Gwendolyn
    Underwood, Patrick
    Cioffi, Jessica
    Trevino, Jose G.
    Hughes, Steven J.
    HPB, 2021, 23 (08) : 1196 - 1200
  • [28] Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
    Nara, Satoshi
    Esaki, Minoru
    Ban, Daisuke
    Takamoto, Takeshi
    Shimada, Kazuaki
    Ioka, Tatsuya
    Okusaka, Takuji
    Ishii, Hiroshi
    Furuse, Junji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1353 - 1363
  • [29] Neoadjuvant and Adjuvant Therapy Does Not Improve Survival in Resected Biliary Cancers
    Glazer, E. S.
    Ellis, V. G.
    Abdalla, E. K.
    Vauthey, J. N.
    Curley, S. A.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S89 - S89
  • [30] A pilot study of gut microbiome modulation to enable efficacy of neoadjuvant checkpointbased immunotherapy (IO) following chemotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Wu, Linda
    Ang, Celina
    Pintova, Sofya
    Sung, Max W.
    Kozuch, Peter
    Dharmapuri, Sirish
    Cohen, Noah A.
    Schwartz, Myron E.
    Mandeli, John P.
    Saxena, Deepak
    Cohen, Deirdre Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS759 - TPS759
12345